½ÃÀ庸°í¼­
»óǰÄÚµå
1685730

¾È°ú¿ë ÀǾàǰ : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ, Åë°è, ¼ºÀå ¿¹Ãø(2025-2030³â)

Ophthalmic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾È°ú¿ë ÀǾàǰ ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 374¾ï 9,000¸¸ ´Þ·¯, ¿¹Ãø ±â°£(2025-2030³â)ÀÇ CAGRÀº 8.24%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 557¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Ophthalmic Drugs-Market-IMG1

¾÷°èÀÇ Çõ½Å°ú È®´ë¸¦ ÃËÁøÇÏ´Â ´Ù¾çÇÑ ¿äÀο¡ ÈûÀÔ¾î ÇöÀúÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ´«°ú °ü·ÃµÈ Áúº´ÀÇ À¯º´·ü Áõ°¡¿Í ½ÃÀå Àü¸ÁÀ» À籸¼ºÇÏ´Â ÀǾàǰ °³¹ß ±â¼úÀÇ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù.

¾÷°è¸¦ Çü¼ºÇÏ´Â ¸Þ°¡ µ¿Çâ : ¾ÈÁúȯÀÇ ¼¼°è Áõ°¡, Àα¸ °í·ÉÈ­, ¾à¹° Á¦Á¦ ±â¼úÀÇ Áøº¸°¡ ½ÃÀå ¼ºÀåÀÇ °ß°íÇÑ ±â¹ÝÀ̵ǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº ƯÁ¤ »ê¾÷ ÃËÁø¿äÀΰú ÇÔ²² ¾È°ú¿ë ÀǾàǰ ¾÷°è¸¦ »õ·Î¿î ³ôÀÌ·Î ²ø¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù.

´«°ú °ü·ÃµÈ Àå¾Ö ¹ß»ý·ü ¹× À¯º´·ü Áõ°¡ : ½Ã·Â Àå¾Ö¸¦ °¡Áø »ç¶÷ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. National Eye InstituteÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2030³â±îÁö ¿¬·É Ȳ¹Ý º¯¼ºÀÌ ¹Ì±¹¿¡¼­ 370¸¸ ¸í¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °°Àº Ãâó´Â ³ì³»ÀåÀÌ 2030³â±îÁö 430¸¸ ¸íÀÇ ¹Ì±¹Àο¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ÃßÁ¤ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾ÈÁúȯÀÇ ºÎ´ãÀº »õ·Ó°í È¿°úÀûÀÎ ¾È°ú Ä¡·á¿¡ ´ëÇÑ ±ä±ÞÇÑ Çʿ伺À» °­Á¶ÇÏ°í ½ÃÀåÀ» ÀüÁø½Ãŵ´Ï´Ù.

½Å¾à °³¹ß°ú °ü·ÃµÈ ¿¬±¸°³¹ß Áõ°¡ : ¾È°ú¿ë ÀǾàǰÀÇ ¼¼°è ½ÃÀå Á¶»ç¿¡ ÀÇÇÏ¸é ¾÷°è´Â ½Å±Ô Ä¡·á ¼Ö·ç¼ÇÀÇ Ã¢ÃâÀ» ¸ñÀûÀ¸·Î ÇÏ´Â R&D Ȱµ¿ Áõ°¡·Î ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè°ú ÀǾàǰ ½ÂÀÎ Áõ°¡´Â ÀÌ µ¿ÇâÀ» ºÎ°¢Çϰí ÀÖ½À´Ï´Ù. 2023³â, FDA´Â ¾È±¸ °ÇÁ¶¸¦ À§ÇÑ »õ·Î¿î Ç׿°ÁõÁ¦ CyclASolÀÇ ½Å¾à ½ÅûÀ» ¼ö¶ôÇß½À´Ï´Ù. ¸¶Âù°¡Áö·Î, Xbrane Biopharma AB¿Í STADA Arzneimittel AG¿¡ ÀÇÇÑ ¶ó´ÏºñÁÖ¸¿ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ À¯·´ Ãâ½Ã´Â ºñ¿ë È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀÇ ±ÞÁõÀ» º¸¿©ÁÝ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ÀǾàǰÀº Ä¡·á ¿µ¿ªÀ» È®´ëÇÏ°í ½ÃÀå ¼ºÀå·üÀ» ²ø¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù.

º´¿ë¿ä¹ý °³¹ß¿¡ ´ëÇÑ °ü½É Áõ°¡ : ¾È°ú¿ë ÀǾàǰ ½ÃÀå¿¡¼­´Â º´¿ë¿ä¹ý¿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á´Â º¹ÀâÇÑ ¾ÈÁúȯ °ü¸®¿¡ Ź¿ùÇÑ Ä¡·á È¿°ú¸¦ Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù, Tenpoint Therapeutics´Â º¯¼º ¾ÈÁúȯ°ú ½Î¿ì´Â °ÍÀ» ¸ñÇ¥·Î Ãâ½Ã ¼±ÁøÀ» ÀÚ¸£±â À§ÇÑ ÀÚ±ÝÀ» È®º¸Çß½À´Ï´Ù. ÀÌ È¸»ç´Â ´Ù¾çÇÑ ¼¼Æ÷ ±â¹Ý Ä¡·áÁ¦¸¦ °áÇÕÇÏ°í °³º° »ç·Ê¿¡ ¸Â´Â Ä¡·á¸¦ ¼öÇàÇÏ´Â °ÍÀ» Àü¹®À¸·Î ÇÕ´Ï´Ù. ÀÌ È¸»çÀÇ Á¢±Ù¹ýÀº ³ëÈ­¿Í À¯Àü¼º ÁúȯÀ¸·Î ÀÎÇÑ ¼Õ»óµÈ ¾È±¸ ¼¼Æ÷¸¦ ȸÃá½ÃŰ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ÀÌ·¯ÇÑ ÆÄÆ®³Ê½ÊÀº ÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ°í ¾ð¸ÞÆ® ¸ÞµðÄà ¿ä±¸¿¡ ´ëÀÀÇÔÀ¸·Î½á ½ÃÀå È®´ë¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ »ê¾÷Àº ÀÌ·¯ÇÑ ½ÃÀå µ¿Çâ°ú °³¹ß¿¡ °ßÀÎµÇ¾î ²ÙÁØÇÑ ¼ºÀå ±Ëµµ¸¦ Ÿ°í ÀÖ½À´Ï´Ù. ÀǾàǰ Çõ½Å, °³ÀÎÈ­ Ä¡·á, ¾È°ú ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀÇ ÇâÈÄ Áøº¸´Â °è¼Ó ¾÷°è¸¦ Çü¼ºÇØ ³ª°¥ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ´« °Ç°­¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀǽÄÀÌ ³ô¾ÆÁö°í Á¶±â °³ÀÔÀÌ ´õ¿í Áß¿äÇØÁü¿¡ µû¶ó ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù.

¾È°ú¿ë ÀǾàǰ ½ÃÀå µ¿Çâ

󹿾à : ¾È°ú Ä¡·áÀÇ ¿øµ¿·Â

ºÎ¹® °³¿ä : 󹿾àÀº ¾È°ú Ä¡·á¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ³ì³»Àå, ¾È±¸°ÇÁ¶Áõ, ¸Á¸· Áúȯ µî ±¤¹üÀ§ÇÑ Áõ»ó¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰÀº È¿´É°ú Á¤È®µµ°¡ ³ô±â ¶§¹®¿¡ ÀÇÇÐÀû ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÕ´Ï´Ù. ó¹æÀü ¾È°ú Ä¡·áÁ¦´Â ½ÃÀå Á¡À¯À²ÀÇ ¾à 65%¸¦ Â÷ÁöÇÏ¸ç ¾È°ú Ä¡·á °ü¸®¿¡¼­ Áö¹èÀûÀÎ ¿ªÇÒÀ» º¸¿©ÁÝ´Ï´Ù.

¼ºÀåÀÇ ¿øµ¿·Â : ³ëÈ­ Ȳ¹Ý º¯¼º°ú ³ì³»Àå°ú °°Àº ¸¸¼º ¾ÈÁúȯÀÇ À¯º´·üÀÇ »ó½ÂÀÌ Ã³¹æ ¾È°ú ¾à ¼ö¿ä¸¦ ²ø¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. ¼­¹æÇü ±â¼ú°ú º´¿ë ¿ä¹ýÀÇ Áøº¸·Î ȯÀÚÀÇ ÄÄÇöóÀÌ¾ð½º¿Í Ä¡·á ¼ºÀûÀÌ ´õ¿í Çâ»óµÇ¾ú½À´Ï´Ù. ¼¼°èÀÇ °í·ÉÈ­ »çȸ´Â ƯÈ÷ ÀÌ·¯ÇÑ Áúº´¿¡ °É¸®±â ½±°í, ¾÷°èÀÇ ¿¬±¸°³¹ß ³ë·Â Áõ°¡¿Í ÇÔ²² ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°æÀï ±¸µµ : ó¹æ¾à ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº °æÀï·ÂÀ» ³ôÀ̱â À§ÇØ ±â¼ú Çõ½Å¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. À¯¸®Ã¼ ³» ÀÓÇöõÆ®¿Í °°Àº °í±Þ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³¹ßÀº º¹ÀâÇÑ ¾ÈÁúȯ¿¡ ´ëÇÑ »õ·Î¿î ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Àü·«Àû Á¦ÈÞ¿Í Àμö´Â Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇϰí, ¸ÂÃãÇü ÀÇ·áÀÇ »ó½ÂÀº Ç¥Àû Ä¡·áÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª À¯ÀüÀÚ Ä¡·á¿Í Àç»ý ÀÇÇÐÀ» Æ÷ÇÔÇÑ ÀáÀçÀûÀΠȥ¶õÀÌ ½ÃÀåÀ» À籸¼º ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ºÏ¹Ì : ¾È°ú ÀÇ·á Çõ½ÅÀÇ °ßÀοª

Áö¿ª ¿ªÇÐ : ºÏ¹Ì´Â °è¼ÓÇØ¼­ ¼¼°è ¾È°ú¿ë ÀǾàǰ ½ÃÀå ±Ô¸ð¸¦ ¼±µµÇϰí ÀÖÀ¸¸ç, °­·ÂÇÑ ¼ºÀå°ú Çõ½ÅÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. °íµµ·Î ¹ß´ÞÇÑ ÇコÄɾî ÀÎÇÁ¶ó¿Í °­·ÂÇÑ ½ÃÀå Á¸Àç·Î ÀÎÇØ ºÏ¹Ì´Â 2024³âºÎÅÍ 2029³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 8% ÀÌ»óÀ¸·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ´Â °ÍÀº ±â¼úÀÇ Áøº¸, ÇコÄɾî ÅõÀÚ Áõ°¡, ´«ÀÇ °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡ÀÔ´Ï´Ù.

¸¶ÄÏ Ä«Å»¸®½ºÆ® : ºÏ¹Ì°¡ ¾È°ú¿ë ÀǾàǰÀ¸·Î ¿ìÀ§¸¦ Â÷ÁöÇÏ´Â ¿øµ¿·ÂÀ̵Ǵ ¸î °¡Áö ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº °í·ÉÈ­°¡ ÁøÇàµÇ°í ÀÖ¾î »ýȰ½À°ü°ú °ü·ÃµÈ ¾ÈÁúȯÀÌ ¸¸¿¬Çϰí Àֱ⠶§¹®¿¡ ȯÀÚ¼ö°¡ ¸¹½À´Ï´Ù. ¶ÇÇÑ È£ÀÇÀûÀÎ º¸Çè »óȯ Á¤Ã¥°ú Áö¿ø ±ÔÁ¦ ȯ°æÀº ÀǾàǰ ±â¼ú Çõ½Å°ú ȯÀÚ Ä¡·á¿¡ ´ëÇÑ Á¢±ÙÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. »ê¾÷¿¬±¸¿¡ ¿Õ¼ºÇÑ Àڱݰø±Þ°ú Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÁÖ·ÂÀ¸·Î ºÏ¹Ì´Â ¾È°ú¿ë ÀǾàǰ °³¹ßÀÇ ¸®´õ½ÊÀ» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü·«Àû °úÁ¦ ½ÃÀå¿¡¼­ÀÇ ÁöÀ§¸¦ À¯ÁöÇϱâ À§ÇØ ±â¾÷Àº À¯ÀüÀÚ Ä¡·á ¹× Àç»ý ÀÇ·á µîÀÇ ¿¬±¸ ºÐ¾ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Çõ½ÅÀ» °¡¼ÓÈ­Çϱâ À§Çؼ­´Â »ý¸í °øÇÐ ±â¾÷ ¹× Çмú ±â°ü°úÀÇ Çù·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¶ÇÇÑ ¿ø°Ý ÀÇ·á ¹× ÀΰøÁö´É(AI)À» Æ÷ÇÔÇÑ µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÌ ¾È°ú ÀÇ·á¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ±â¾÷Àº ¶ÇÇÑ ÇÏÀÌÅ×Å© ±â¾÷ÀÇ ÁøÀÔ°ú °¡Ä¡ ±â¹Ý ÄÉ¾î ¸ðµ¨¿¡ ÀÇÇÑ °æÀï ±¸µµÀÇ ÀáÀçÀûÀÎ º¯È­¿¡µµ ´ëºñÇØ¾ß ÇÕ´Ï´Ù.

¾È°ú¿ë ÀǾàǰ ¾÷°è °³¿ä

½ÃÀå ¿ªÇÐ : ¼¼°è ±â¾÷ÀÌ ÅëÇÕ »óȲÀ» Áö¹è

ÀÌ ¼¼°èÀÇ ¾÷°è´Â ±¤¹üÀ§ÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ º¸À¯ÇÑ ¼±µµÀû ´Ù±¹Àû Á¦¾à ȸ»ç¿¡ ÀÇÇØ °ÅÀÇ Áö¹èµÇ°í ÀÖ½À´Ï´Ù. ³ë¹ÙƼ½º, ·Î½´, ¸®Á¦³×·Ð µî ÁÖ¿ä ±â¾÷µéÀº ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß ´É·Â°ú °­·ÂÇÑ ÆÇ¸Å¸ÁÀ¸·Î ¾È°ú¿ë ÀǾàǰ ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº ÅëÇյǾî ÀÖÀ¸¸ç ¼Ò¼ö ½ÃÀå ¸®´õ¿Í ÁÖ¿ä ±â¾÷ÀÌ ÃÑ ¸ÅÃâÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ÁøÀÔÀ庮ÀÌ ³ô°í ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ º¹ÀâÇÏ°í ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ½Å±Ô ÁøÀÔ ±â¾÷ÀÌ ±âÁ¸±â¾÷°ú °æÀïÇϱâ´Â ¾î·Æ½À´Ï´Ù.

½ÃÀå ¸®´õ : Çõ½Å°ú ÆÄÀÌÇÁ¶óÀÎÀÇ ÈûÀÌ ¼º°øÀÇ ¿øµ¿·Â

³ë¹ÙƼ½º, ·Î½´, ¸®Á¦³×·Ð ÆÛ¸Ó½´Æ¼ÄÃÁî¿Í °°Àº ÁÖ¿ä ±â¾÷µéÀº ¸Á¸· Áúȯ Ä¡·á ¹× ±âŸ ¾È°ú ¿µ¿ª¿¡¼­ Å« Áøº¸¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ³ë¹ÙƼ½ºÀÇ ¸Á¸·Ä¡·á¿¡ À־ÀÇ ±â¼ú Çõ½Å°ú ¸®Á¦³×·ÐÀÇ ³ëȭȲ¹Ýº¯¼º Ä¡·á¿¡ À־ÀÇ EYLEAÀÇ ¼º°øÀÌ ±× ¿¹ÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ ½ÃÀå ¸®´õ´Â ÇâÈÄ ¼ö³â°£ »ó½Ã°¡ ¿¹Á¤µÈ ¿©·¯ Èıâ ÀÓ»ó Èĺ¸ È­ÇÕ¹°À» º¸À¯ÇÑ °­·ÂÇÑ Á¦Ç° ÆÄÀÌÇÁ¶óÀο¡ ÀÇÇØ °­È­µÇ°í ÀÖ½À´Ï´Ù. ±¤´ëÇÑ ¼¼°è Á¸Àç¿Í °Ç°­ °ü¸® ÀÌÇØ °ü°èÀÚ°£ÀÇ ±íÀº °ü°è°¡ °æÀï ¿ìÀ§¸¦ È®°íÇϰÔÇÕ´Ï´Ù.

¹Ì·¡ ¼º°øÀ» À§ÇÑ Àü·« : ÃæÁ·µÇÁö ¾ÊÀº ¿ä±¸¿Í ½Å±â¼ú¿¡ ÁÖ·Â

ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÀÌ·ç±â À§ÇØ ±â¾÷Àº ¾È°ú ºÎÀ§ÀÇ ¹ÌÃæÁ· ¿ä±¸, ƯÈ÷ ¾È±¸°ÇÁ¶Áõ ¹× ´ç´¢º´¼º ¸Á¸·Áõ°ú °°Àº Ä¡·á¿¡ ÁÖ·ÂÇØ¾ß ÇÕ´Ï´Ù. À¯ÀüÀÚ Ä¡·á³ª ¼­¹æÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ µîÀÇ ½Å±â¼úÀ» Ȱ¿ëÇÏ¸é °æÀï·ÂÀ» ³ôÀÏ ¼ö ÀÖ´Ù°í »ý°¢µË´Ï´Ù. ¿¹¸¦ µé¾î, ³ì³»ÀåÀ» À§ÇÑ Àå±â°£ ÀÛ¿ëÇÏ´Â ¾È±¸ ÀÓÇöõÆ®¸¦ °³¹ßÇÏ´Â ±â¾÷Àº ÀüÅëÀûÀÎ Ä¡·á¿¡¼­ Å« ½ÃÀå Á¡À¯À²À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç°ú °°Àº °í¼ºÀå Áö¿ªÀ¸·ÎÀÇ ÁøÃâÀº Çõ½ÅÀ» ÃËÁøÇϱâ À§ÇØ »ý¸í °øÇÐ ±â¾÷ ¹× ¿¬±¸ ±â°ü°úÀÇ Á¦ÈÞ¿Í ÇÔ²² Áß¿äÇÕ´Ï´Ù.

±âŸ ÇýÅà :

  • ¿¢¼¿ Çü½Ä ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • ¾Ö³Î¸®½ºÆ®¿¡ ÀÇÇÑ 3°³¿ù°£ÀÇ Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ´«°ú °ü·ÃµÈ ÁúȯÀÇ ¹ß»ý·ü°ú À¯º´·ü Áõ°¡
    • ½Å¾à °³¹ß¿¡ °ü·ÃµÈ ¿¬±¸ °³¹ßÀÇ È°¼ºÈ­
    • º´¿ë ¿ä¹ý °³¹ß¿¡ ÁÖ¸ñÀÇ °íÁ¶
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ´ëÁß¾à Æ¯Çã ¸¸·á
    • ½ÅÈï ±¹°¡ÀÇ ÀÇ·á º¸Çè ºÎÁ·
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚ, ¼ÒºñÀÚÀÇ Çù»ó·Â
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°èÀÇ °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • ¾àÁ¦ Ŭ·¡½ºº°
    • Ç׳쳻Àå¾à
    • ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦
    • ¾È°ú¿ë Ç׾˷¹¸£±â, Ç׿°ÁõÁ¦
    • ¸Á¸·¿ë ¾à
    • Ç×°¨¿°Áõ¾à
    • ±âŸ ÀǾàǰ
  • Á¦Ç° À¯Çüº°
    • ÀϹݿë ÀǾàǰ
    • 󹿾à
  • Áö¿ªº°
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Aerie Pharmaceuticals Inc.
    • AbbVie(Allergan)
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Viatris Inc.
    • Regeneron Pharmaceuticals Inc.
    • Santen Pharmaceutical Co. Ltd
    • Alcon
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

Á¦7Àå ½ÃÀå ±âȸ¿Í ¾ÕÀ¸·ÎÀÇ µ¿Çâ

SHW 25.04.01

The Ophthalmic Drugs Market size is estimated at USD 37.49 billion in 2025, and is expected to reach USD 55.71 billion by 2030, at a CAGR of 8.24% during the forecast period (2025-2030).

Ophthalmic Drugs - Market - IMG1

It is witnessing significant growth, underpinned by various factors driving both innovation and expansion in the industry. Key drivers include the increasing prevalence of eye-related disorders and advancements in drug development technologies, which are reshaping the market landscape.

Megatrends Shaping the Industry: The global rise in ocular conditions, an aging population, and advancements in drug formulation technologies are creating robust foundations for market growth. These factors, along with specific industry drivers, are pushing the ophthalmic drugs industry to new heights.

Increasing Incidence and Prevalence of Eye-related Disorders: The growing number of individuals with vision impairment is a major factor driving the market growth. Data from the National Eye Institute projects that by 2030, age-related macular degeneration will impact 3.7 million individuals in the United States. Additionally, the same source estimates that glaucoma will affect 4.3 million Americans by 2030. The high burden of these eye diseases underscores the urgent need for new and effective ophthalmic treatments, driving the market forward.

Rising Research and Development Pertaining to the Development of Novel Drugs: Global ophthalmic drugs market research says that the industry is benefiting from increased R&D activity aimed at creating novel therapeutic solutions. The rise in clinical trials and drug approvals highlights this trend. In 2023, the FDA accepted a New Drug Application for CyclASol, a novel anti-inflammatory product for dry eye disease. Similarly, the European launch of a ranibizumab biosimilar by Xbrane Biopharma AB and STADA Arzneimittel AG showcases the surge in cost-effective treatment options. These innovative drugs are expanding the therapeutic landscape and boosting the market at a decent growth rate.

Increasing Focus on Developing Combination Therapies: The emphasis on combination therapies within the ophthalmic drugs market is growing. These treatments offer superior therapeutic results for managing complex ocular diseases. For instance, in July 2023, Tenpoint Therapeutics secured funding to spearhead its launch aimed at combating degenerative eye diseases. The company specializes in combining various cell-based therapeutics and crafting treatments tailored to individual cases. Their approach centers on rejuvenating eye cells compromised by age-related or inherited ailments. Such partnerships are fueling innovation in the field, accelerating market expansion by addressing unmet medical needs.

Global industry is on a steady growth trajectory, driven by these market trends and developments. Future advancements in drug innovation, personalized treatments, and increased access to eye care will continue to shape the industry. As public awareness around eye health rises and early intervention becomes more critical, the market is poised for sustained growth.

Ophthalmic Drugs Market Trends

Prescription Drugs: Driving Force in Ophthalmic Treatments

Segment Overview: Prescription drugs play a pivotal role in ophthalmic treatments, addressing a wide range of conditions including glaucoma, dry eye, and retinal disorders. These drugs require medical oversight due to their potency and precision. Prescription ophthalmic medications account for approximately 65% of the market share, illustrating their dominant role in eye care management.

Growth Drivers: The rising prevalence of chronic eye disorders, such as age-related macular degeneration and glaucoma, is boosting demand for prescription ophthalmic drugs. Advances in sustained-release technologies and combination therapies are further enhancing patient compliance and treatment outcomes. The global aging population is particularly susceptible to these disorders, which, along with increasing industry research and development efforts, are expected to bolster the growth of this segment.

Competitive Landscape: Leading companies in the prescription drug market are focusing on innovation to gain a competitive edge. The development of advanced drug delivery systems, such as intravitreal implants, is providing new solutions for complex eye conditions. Strategic collaborations and acquisitions are expanding product portfolios, while the rise of personalized medicine is driving the development of targeted therapies. However, potential disruptions, including gene therapies and regenerative medicine, may reshape the market.

North America: Leading the Charge in Ophthalmic Innovation

Regional Dynamics: North America continues to lead the global ophthalmic drugs market size, exhibiting robust growth and innovation. With a highly developed healthcare infrastructure and strong market presence, North America is expected to expand at a compound annual growth rate (CAGR) of over 8% from 2024 to 2029. This growth is fueled by technological advancements, increasing healthcare investments, and rising awareness around eye health.

Market Catalysts: Several factors are driving North America's dominance in ophthalmic drugs. The region's aging population and the prevalence of lifestyle-related ocular disorders contribute to a significant patient base. Favorable reimbursement policies and a supportive regulatory environment also encourage drug innovation and patient access to treatments. With strong funding for industry research and a focus on precision medicine, North America is expected to maintain its leadership in ophthalmic drug development.

Strategic Imperatives: To maintain their market position, companies are investing in research areas like gene therapy and regenerative medicine. Collaborations with biotech firms and academic institutions are essential for accelerating innovation. Additionally, digital health solutions, including telemedicine and artific ial intelligence (AI), are increasingly integrated into eye care. Companies should also prepare for potential shifts in the competitive landscape, driven by tech entrants and value-based care models.

Ophthalmic Drugs Industry Overview

Market Dynamics: Global Players Dominate Consolidated Landscape

This global industry is largely controlled by major multinational pharmaceutical firms with broad product portfolios. Leading companies such as Novartis, Roche, and Regeneron hold substantial ophthalmic drugs market share due to their expansive R&D capabilities and strong distribution networks. The market is consolidated, with a few market leaders and key players dominating a large portion of the total revenue. High entry barriers, complex regulatory frameworks, and the need for significant investment in R&D make it challenging for new entrants to compete with established players.

Market Leaders: Innovation and Pipeline Strength Drive Success

Leading companies like Novartis, Roche, and Regeneron Pharmaceuticals Inc. have made significant strides in retinal disease treatments and other areas of ophthalmology. Novartis' innovations in retinal therapies and Regeneron's success with EYLEA in treating age-related macular degeneration exemplify this. These market leaders are also bolstered by their strong product pipelines, with several late-stage clinical candidates set to launch in the coming years. Their vast global presence and deep relationships with healthcare stakeholders solidify their competitive advantage.

Strategies for Future Success: Focus on Unmet Needs and Emerging Technologies

To capture future market growth, companies must focus on unmet needs in ophthalmology, particularly in treating conditions like dry eye disease and diabetic retinopathy. Leveraging emerging technologies such as gene therapies and sustained-release drug delivery systems could provide a competitive edge. Companies developing long-acting intraocular implants for glaucoma, for instance, could capture significant market share from traditional treatments. Expansion into high-growth regions such as the Asia-Pacific will be critical, alongside partnerships with biotechnology firms and research institutions to foster innovation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence and Prevalence of Eye-related Disorders
    • 4.2.2 Rising Research and Development Pertaining to the Development of Novel Drugs
    • 4.2.3 Increasing Focus on Developing Combination Therapies
  • 4.3 Market Restraints
    • 4.3.1 Loss of Patent Protection for Popular Drugs
    • 4.3.2 Lack of Health Insurance in the Developing Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value- USD)

  • 5.1 By Drug Class
    • 5.1.1 Anti-glaucoma Drugs
    • 5.1.2 Dry Eye Drugs
    • 5.1.3 Ophthalmic Anti-allergy/Inflammatory
    • 5.1.4 Retinal Drugs
    • 5.1.5 Anti-infective Drugs
    • 5.1.6 Other Drugs
  • 5.2 By Product Type
    • 5.2.1 OTC Drugs
    • 5.2.2 Prescription Drugs
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aerie Pharmaceuticals Inc.
    • 6.1.2 AbbVie (Allergan)
    • 6.1.3 Bausch Health Companies Inc.
    • 6.1.4 Bayer AG
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Novartis AG
    • 6.1.7 Viatris Inc.
    • 6.1.8 Regeneron Pharmaceuticals Inc.
    • 6.1.9 Santen Pharmaceutical Co. Ltd
    • 6.1.10 Alcon
    • 6.1.11 Sun Pharmaceutical Industries Ltd.
    • 6.1.12 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦